Prenatal intake of certain immunosuppressive drugs may carry risks

10/23/2013 | HealthDay News

Prenatal exposure to transplant rejection drugs called mycophenolic acid products was associated with a higher risk of miscarriage, perinatal death and birth defects, according to a study to be presented at an American Society of Nephrology meeting. Researchers tracked 277 female kidney transplant patients and found that those who stopped taking the anti-rejection drugs prior to conception had a greater chance of live births and lower risk of birth defects and miscarriages than those who continued taking the drugs. The risk of kidney problems was not higher in women who discontinued treatment.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC